Watson has filed ANDA with paragraph IV certification for generic version of Crestor(TM) (Rosuvastatin Cacium) and in response of that, AStraZeneca has filed law suit against watson in U.S. District Court for the District of Delaware seeking to block the company from selling a generic product prior to the patent expiration set for March 30, 2013.
(Source: www.forbes.com)
No comments:
Post a Comment